Overbrook Management Corp’s Celldex Therapeutics CLDX Stock Holding History

Overbrook Management Corp’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$429K	Hold	11,537	–	–	0.06%	49
2026 Q1	$366K	Hold	11,537	–	–	0.07%	44
2025 Q4	$313K	Buy	11,537 +2,740	+31%	+$72.2K	0.05%	43
2025 Q3	$228K	Buy	+8,797	New	+$204K	0.04%	44
2024 Q4	–	Sell	-6,837	Closed	-$232K	–	53
2024 Q3	$232K	Hold	6,837	–	–	0.05%	51
2024 Q2	$253K	Sell	6,837 -252	-4%	-$9.51K	0.06%	50
2024 Q1	$298K	Sell	7,089 -555	-7%	-$22.8K	0.08%	51
2023 Q4	$303K	Hold	7,644	–	–	0.06%	55
2023 Q3	$210K	Sell	7,644 -119	-2%	-$3.73K	0.05%	58
2023 Q2	$263K	Hold	7,763	–	–	0.06%	59
2023 Q1	$279K	Sell	7,763 -312	-4%	-$13.5K	0.07%	63
2022 Q4	$360K	Hold	8,075	–	–	0.1%	56
2022 Q3	$227K	Sell	8,075 -165	-2%	-$5.06K	0.06%	69
2022 Q2	$222K	Hold	8,240	–	–	0.06%	78
2022 Q1	$281K	Buy	+8,240	New	+$263K	0.06%	77
2019 Q1	–	Sell	-3,241	Closed	-$10K	–	71
2018 Q4	$10K	Hold	3,241	–	–	﹤0.01%	71
2018 Q3	$22K	Hold	3,241	–	–	﹤0.01%	74
2018 Q2	$24K	Hold	3,241	–	–	﹤0.01%	72
2018 Q1	$113K	Hold	3,241	–	–	0.02%	75
2017 Q4	$138K	Hold	3,241	–	–	0.03%	76
2017 Q3	$139K	Sell	3,241 -500	-13%	-$18.7K	0.03%	70
2017 Q2	$139K	Buy	+3,741	New	+$165K	0.03%	77

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Overbrook Management Corp's CLDX Position: Q2 2026 in Review

Overbrook Management Corp held its Celldex Therapeutics (CLDX) position steady in Q2 2026 at 11,537 shares worth $429K. The position accounts for 0.06% of the portfolio, ranked #49.

Overbrook Management Corp first reported a position in CLDX in Q2 2017 and has held it in 22 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Overbrook Management Corp held 11,537 shares of Celldex Therapeutics worth $429K as of Q2 2026.
Overbrook Management Corp left its Celldex Therapeutics share count unchanged in Q2 2026.
Celldex Therapeutics made up 0.06% of Overbrook Management Corp's portfolio in Q2 2026, its #49 holding.
Overbrook Management Corp first reported a position in Celldex Therapeutics in Q2 2017 and has held it in 22 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Overbrook Management Corp's 13F filing for Q2 2026, filed 30 Jul 2026.